Target Therapeutics announced an agreement with BaltExtrusion of Paris to distribute neurological products in theUnited States and Canada, including Balt's "Magic" line of flow-directed catheters and its neuro-guiding catheters.
Target (NASDAQ:TGET) of San Jose, Calif., will keep distributionrights for three years, with an option to extend the agreementfor another three years if certain sales and regulatorymilestones are met.
Balt's Magic line of catheters is used in the treatment ofvascular malformations of the brain characterized by rapidblood flow.
(c) 1997 American Health Consultants. All rights reserved.